These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24907636)

  • 1. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
    Mittendorf EA; Clifton GT; Holmes JP; Schneble E; van Echo D; Ponniah S; Peoples GE
    Ann Oncol; 2014 Sep; 25(9):1735-1742. PubMed ID: 24907636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Mittendorf EA; Clifton GT; Holmes JP; Clive KS; Patil R; Benavides LC; Gates JD; Sears AK; Stojadinovic A; Ponniah S; Peoples GE
    Cancer; 2012 May; 118(10):2594-602. PubMed ID: 21989902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
    Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
    Patil R; Clifton GT; Holmes JP; Amin A; Carmichael MG; Gates JD; Benavides LH; Hueman MT; Ponniah S; Peoples GE
    J Am Coll Surg; 2010 Feb; 210(2):140-7. PubMed ID: 20113933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
    Mittendorf EA; Ardavanis A; Litton JK; Shumway NM; Hale DF; Murray JL; Perez SA; Ponniah S; Baxevanis CN; Papamichail M; Peoples GE
    Oncotarget; 2016 Oct; 7(40):66192-66201. PubMed ID: 27589688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
    J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Amin A; Benavides LC; Holmes JP; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Storrer CE; Jama YH; Craig D; Stojadinovic A; Ponniah S; Peoples GE
    Cancer Immunol Immunother; 2008 Dec; 57(12):1817-25. PubMed ID: 18392824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
    Mittendorf EA; Ardavanis A; Symanowski J; Murray JL; Shumway NM; Litton JK; Hale DF; Perez SA; Anastasopoulou EA; Pistamaltzian NF; Ponniah S; Baxevanis CN; von Hofe E; Papamichail M; Peoples GE
    Ann Oncol; 2016 Jul; 27(7):1241-8. PubMed ID: 27029708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
    Brown TA; Byrd K; Vreeland TJ; Clifton GT; Jackson DO; Hale DF; Herbert GS; Myers JW; Greene JM; Berry JS; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwel GL; Peoples GE
    Cancer Med; 2019 Aug; 8(10):4678-4687. PubMed ID: 31274231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
    Carmichael MG; Benavides LC; Holmes JP; Gates JD; Mittendorf EA; Ponniah S; Peoples GE
    Cancer; 2010 Jan; 116(2):292-301. PubMed ID: 19924797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
    Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
    Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.
    Clifton GT; Litton JK; Arrington K; Ponniah S; Ibrahim NK; Gall V; Alatrash G; Peoples GE; Mittendorf EA
    Ann Surg Oncol; 2017 Aug; 24(8):2161-2167. PubMed ID: 28315060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development and use of the E75 (HER2 369-377) peptide vaccine.
    Clifton GT; Peoples GE; Mittendorf EA
    Future Oncol; 2016 Jun; 12(11):1321-9. PubMed ID: 27044454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
    Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
    Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.
    Schneble EJ; Berry JS; Trappey FA; Clifton GT; Ponniah S; Mittendorf E; Peoples GE
    Immunotherapy; 2014; 6(5):519-31. PubMed ID: 24896623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
    Chick RC; Clifton GT; Hale DF; Vreeland TJ; Hickerson AT; Kemp Bohan PM; McCarthy PM; Litton JK; Alatrash G; Murthy RK; Qiao N; Philips A; Lukas J; Holmes JP; Mittendorf EA; Peoples GE
    Clin Immunol; 2021 Apr; 225():108679. PubMed ID: 33485895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ.
    O'Shea AE; Clifton GT; Qiao N; Heckman-Stoddard BM; Wojtowicz M; Dimond E; Bedrosian I; Weber D; Garber JE; Husband A; Pastorello R; Lee JJ; Hernandez M; Liu DD; Vornik LA; Brown PH; Alatrash G; Peoples GE; Mittendorf EA
    Cancer Prev Res (Phila); 2023 Jun; 16(6):333-341. PubMed ID: 37259799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.
    Clifton GT; Hale D; Vreeland TJ; Hickerson AT; Litton JK; Alatrash G; Murthy RK; Qiao N; Philips AV; Lukas JJ; Holmes JP; Peoples GE; Mittendorf EA
    Clin Cancer Res; 2020 Jun; 26(11):2515-2523. PubMed ID: 32071118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.